CSF1R and neoplasm: In addition to CSF1/CSF1R blockade, macrophage reprogramming using HDAC inhibitors or agonistic anti-CD40 antibodies increases the expression of PD-L1 on macrophages, which limits the anti-tumor effect of reprogrammed TAMs (54, 55).